RU2017118580A - FUNCTIONALIZED MORPHOLINYLANTHRACYCLINE DERIVATIVES - Google Patents
FUNCTIONALIZED MORPHOLINYLANTHRACYCLINE DERIVATIVES Download PDFInfo
- Publication number
- RU2017118580A RU2017118580A RU2017118580A RU2017118580A RU2017118580A RU 2017118580 A RU2017118580 A RU 2017118580A RU 2017118580 A RU2017118580 A RU 2017118580A RU 2017118580 A RU2017118580 A RU 2017118580A RU 2017118580 A RU2017118580 A RU 2017118580A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- absent
- ant
- alkyl
- morpholinylanthracycline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (95)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14191952 | 2014-11-05 | ||
EP14191952.2 | 2014-11-05 | ||
PCT/EP2015/075749 WO2016071418A1 (en) | 2014-11-05 | 2015-11-04 | Functionalized morpholinyl anthracycline derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017118580A true RU2017118580A (en) | 2018-12-05 |
RU2017118580A3 RU2017118580A3 (en) | 2019-03-26 |
RU2715902C2 RU2715902C2 (en) | 2020-03-04 |
Family
ID=51868061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017118580A RU2715902C2 (en) | 2014-11-05 | 2015-11-04 | Functionalised derivatives of morpholinylanthracycline |
Country Status (8)
Country | Link |
---|---|
US (1) | US20170312290A1 (en) |
EP (1) | EP3215513B1 (en) |
JP (1) | JP6785780B2 (en) |
KR (1) | KR102562864B1 (en) |
CN (1) | CN107001384A (en) |
ES (1) | ES2735375T3 (en) |
RU (1) | RU2715902C2 (en) |
WO (1) | WO2016071418A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3464294B1 (en) | 2016-05-30 | 2022-07-13 | Toxinvent Oü | Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment |
US20220249676A1 (en) * | 2019-06-05 | 2022-08-11 | Boston Scientific Scimed, Inc. | Click chemistry capturable platinum-based antineoplastic agents |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3803124A (en) | 1968-04-12 | 1974-04-09 | Farmaceutici It Soc | Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives |
GB1511680A (en) * | 1975-11-18 | 1978-05-24 | Farmaceutici Italia | Daunosaminyl anthracyclinones |
JPS63175745A (en) | 1987-01-16 | 1988-07-20 | Mitsubishi Pencil Co Ltd | Production of carbon furnace for atomic absorption analysis |
NZ224252A (en) | 1987-04-21 | 1991-09-25 | Erba Carlo Spa | An anthracycline glycoside and its preparation |
GB8804429D0 (en) | 1988-02-25 | 1988-03-23 | Erba Carlo Spa | New 4-demethyl-4-0-(fluorobenzensulfonyl)anthracycline glycosides |
GB2225781A (en) | 1988-05-13 | 1990-06-13 | Erba Carlo Spa | 10-Noranthracyclines |
GB8902709D0 (en) | 1989-02-07 | 1989-03-30 | Erba Carlo Spa | New 4'-epi-4'-amino anthracyclines |
GB8905668D0 (en) * | 1989-03-13 | 1989-04-26 | Erba Carlo Spa | New 3'-(4-morpholinyl)-and 3'-(2-methoxy-4-morpholinyl)-anthracycline derivatives |
EP0434960B1 (en) | 1989-12-19 | 1996-09-18 | PHARMACIA S.p.A. | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
GB2296495B (en) | 1994-12-23 | 1998-04-15 | Erba Carlo Spa | Anthracycline derivatives |
GB2315067B (en) | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
GB0018240D0 (en) * | 2000-07-25 | 2000-09-13 | Pharmacia & Upjohn Spa | Polymeric conjugates of antitumor agents |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
AU2003282624A1 (en) | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
BRPI0408494A (en) * | 2003-03-18 | 2006-04-04 | Pharmacia Italia Spa | combined tumor therapy comprising nemorubicin with radiation therapy |
US20050152906A1 (en) * | 2003-06-30 | 2005-07-14 | Avigdor Levanon | Specific human antibodies |
US7282590B2 (en) | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
MXPA06012144A (en) | 2004-04-21 | 2007-01-31 | Alza Corp | Polymer conjugate releasable under mild thiolytic conditions. |
JP5149620B2 (en) | 2004-07-23 | 2013-02-20 | エンドサイト,インコーポレイテッド | Bivalent linker and conjugate thereof |
US8742076B2 (en) * | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
JP6067222B2 (en) * | 2008-07-15 | 2017-01-25 | ジェネンテック, インコーポレイテッド | Anthracycline derivative conjugates, methods for their preparation and their use as antitumor compounds |
MX2013005972A (en) | 2010-12-02 | 2013-08-09 | Nerviano Medical Sciences Srl | Process for the preparation of morpholinyl anthracycline derivatives. |
EP2991993B1 (en) * | 2013-04-29 | 2018-06-06 | Nerviano Medical Sciences S.r.l. | Morpholinyl anthracycline derivatives |
-
2015
- 2015-11-04 EP EP15788447.9A patent/EP3215513B1/en active Active
- 2015-11-04 RU RU2017118580A patent/RU2715902C2/en not_active Application Discontinuation
- 2015-11-04 ES ES15788447T patent/ES2735375T3/en active Active
- 2015-11-04 US US15/522,005 patent/US20170312290A1/en not_active Abandoned
- 2015-11-04 CN CN201580060048.4A patent/CN107001384A/en active Pending
- 2015-11-04 KR KR1020177015263A patent/KR102562864B1/en active IP Right Grant
- 2015-11-04 WO PCT/EP2015/075749 patent/WO2016071418A1/en active Application Filing
- 2015-11-04 JP JP2017542325A patent/JP6785780B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2715902C2 (en) | 2020-03-04 |
WO2016071418A1 (en) | 2016-05-12 |
US20170312290A1 (en) | 2017-11-02 |
CN107001384A (en) | 2017-08-01 |
JP2017534683A (en) | 2017-11-24 |
RU2017118580A3 (en) | 2019-03-26 |
KR20170078833A (en) | 2017-07-07 |
ES2735375T3 (en) | 2019-12-18 |
EP3215513B1 (en) | 2019-05-08 |
EP3215513A1 (en) | 2017-09-13 |
JP6785780B2 (en) | 2020-11-18 |
KR102562864B1 (en) | 2023-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005219733B2 (en) | Hyaluronic acid-methotrexate conjugate | |
TW508357B (en) | Novel compounds, the preparation and use thereof | |
BR112020020349A2 (en) | BICYCLIC PEPTIDE COMPLEXES IN HETEROTANDEM | |
JP2016505586A5 (en) | ||
KR970042553A (en) | Camptothecin derivatives | |
TW533217B (en) | Dolastatin 15 derivatives | |
RU2008126305A (en) | NEW PEPTID | |
Dal Pozzo et al. | Novel tumor-targeted RGD peptide–camptothecin conjugates: Synthesis and biological evaluation | |
TW201004647A (en) | Novel dual targeting antitumoural conjugates | |
ES2321114T3 (en) | CONJUGATED CAMPTOTECINS IN POSITION 7 WITH CYCLICAL PEPTIDES AS CITOSTATION AGENTS. | |
RU2011130831A (en) | ANTI-VIRUS COMPOUNDS | |
AR061097A1 (en) | PROCEDURE FOR SYNTHESIZING THYLOSINS | |
WO1999011659A1 (en) | Novel cyclic tetrapeptide derivatives and medicinal use thereof | |
CZ285980B6 (en) | Peptide derivative, process for preparing sulfate salt thereof and pharmaceutical preparation in which the derivative is comprised | |
DE602004032553D1 (en) | POLYACETAL DRUG CONJUGATES AS A RELEASE SYSTEM | |
NZ715646A (en) | Antibody drug conjugates | |
RU2008116674A (en) | NEW CYCLIC PEPTIDE COMPOUNDS | |
JP2017521486A (en) | Peptide-drug conjugate | |
RU2017118580A (en) | FUNCTIONALIZED MORPHOLINYLANTHRACYCLINE DERIVATIVES | |
AR033680A1 (en) | USEFUL TRICICLIC COMPOUNDS AS INHIBITORS OF FARNESIL PROTEINO TRANSFERASA AND ITS USE FOR THE MANUFACTURE OF MEDICINES AS ANTITUMOR AGENTS | |
JP2017529386A5 (en) | ||
JP2002512590A (en) | Dolastatin tetrapeptide derivatives as antitumor agents | |
JP2001514659A (en) | Combination of dolastatin-15 derivative and taxane | |
EP1961759A1 (en) | Integrin targeted cyclopeptide ligands, their preparation and use | |
CA2562572A1 (en) | Camptothecin derivatives conjugated in position 20 with integrin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20191024 |
|
FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20191024 |